// App-Quantinova.ai

TPS3112 : A phase I study of pembrolizumab in combination with enadenotucirev (EnAd) (SPICE) in subjects with metastatic or advanced carcinoma.

Researchers

Presenter

  • Wael A. Harb

Principal Investigators

  • Virginie Cerec

  • Hilary McElwaine-Johnn

  • Brian Champion

  • Simon Alvis

  • Nitin Jain

  • Christopher Ellis

  • Kerry Fisher

  • John William Beadle

Medical Centers

  • Horizon Oncology Center, Lafayette, IN

  • PsiOxus Therapeutics Ltd., Abingdon, United Kingdom

  • PsiOxus Therapeutics Ltd., Abingdon, United Kingdom

  • PSIOXUS, Abingdon, United Kingdom

  • Psioxus Therapeutics LTD, Ramsden Heath, Essex, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • PsiOxus Therapeutics

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Dental and Oral Health

Disease

  • Salivary gland cancer

Biomarkers

  • N/A

Drug/Treatment

  • enadenotucirev

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Dose Escalation

  • Cohort

Phase

  • I

Study Id's

  • NCT02636036

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved